Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Dino Rossi Biography and Net Worth

Director of Krystal Biotech

Dino A. Rossi serves as Independent Director of the Company. Mr. Rossi was previously employed by Balchem Corporation (Nasdaq: BCPC), where he served as Chief Executive Officer and President from October 1997 to April 2015, Chief Financial Officer from April 1996 to January 2004 and Treasurer from June 1996 to June 2003, as well as Executive Chairman from September 2015 to December 2016. He has also previously served as Vice President, Finance & Administration of Norit Americas Inc., a wholly owned subsidiary of Norit N.V. and Vice President, finance and Administration of Oakite Products Inc. Mr. Rossi is currently on the board of directors of Chroma Color Concentrates and Polytek Development Corporation. He also previously served on the boards of Elite Comfort Solutions from January 2017 to January 2019 and of Scientific Learning Corp from February 2010 to December 2011. Mr. Rossi holds a BS in Accounting from West Virginia University.

What is Dino A. Rossi's net worth?: The estimated net worth of Dino A. Rossi is at least $13.79 million as of March 1st, 2023. Mr. Rossi owns 83,691 shares of Krystal Biotech stock worth more than $13,794,788 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Rossi may own. Learn More about Dino A. Rossi's net worth.
How do I contact Dino A. Rossi?: The corporate mailing address for Mr. Rossi and other Krystal Biotech executives is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. Krystal Biotech can also be reached via phone at (412) 586-5830 and via email at [email protected]. Learn More on Dino A. Rossi's contact information.
Has Dino A. Rossi been buying or selling shares of Krystal Biotech?: Dino A. Rossi has not been actively trading shares of Krystal Biotech in the last ninety days. Most recently, Dino A. Rossi sold 40,000 shares of the business's stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $83.25, for a transaction totalling $3,330,000.00. Following the completion of the sale, the director now directly owns 83,691 shares of the company's stock, valued at $6,967,275.75. Learn More on Dino A. Rossi's trading history.
Who are Krystal Biotech's active insiders?: Krystal Biotech's insider roster includes Julian Gangolli (Director), Daniel Janney (Director), Krish Krishnan (CEO), Suma Krishnan (COO), Kathryn Romano (CAO), and Dino Rossi (Director). Learn More on Krystal Biotech's active insiders.
Are insiders buying or selling shares of Krystal Biotech?: In the last year, insiders at the sold shares 8 times. They sold a total of 135,587 shares worth more than $23,275,691.17. The most recent insider tranaction occured on December, 13th when insider Suma Krishnan sold 25,000 shares worth more than $4,119,500.00. Insiders at Krystal Biotech own 14.1% of the company. Learn More about insider trades at Krystal Biotech.
Information on this page was last updated on 12/13/2024.

Dino A. Rossi Insider Trading History at Krystal Biotech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/1/2023	Sell	40,000	$83.25	$3,330,000.00	83,691

Dino A. Rossi Buying and Selling Activity at Krystal Biotech

Krystal Biotech Company Overview

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Today's Range

Now: $164.83

$159.20

$165.98

50 Day Range

MA: $180.18

$156.64

$199.61

2 Week Range

Now: $164.83

$107.50

$219.34

Volume

892,241 shs

Average Volume

325,570 shs

Market Capitalization

$4.74 billion

P/E Ratio

93.12

Dividend Yield

N/A

Beta

0.8

Most People Are Dead Wrong.

From Brownstone Research | Ad